Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Heska (HSKA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Heska (HSKA)
by Zacks Equity Research
Heska (HSKA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Heska (HSKA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022
by Zacks Equity Research
Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.
Heska (HSKA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 555.56% and 11.48%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Heska (HSKA) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 166.67% and 16.66%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska (HSKA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 44.00% and -8.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska (HSKA) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 133.33% and -1.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 25.00% and 2.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
An ETF to Capitalize on the Booming Pet Industry
by Neena Mishra
The pet industry is growing at about twice the rate of GDP; here is how investors can benefit from this trend.
Heska (HSKA) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 31.43% and -0.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska (HSKA) Tops Q2 Earnings Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 41.18% and -1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Heska (HSKA) Might Surprise This Earnings Season
by Zacks Equity Research
Heska (HSKA) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
by Zacks Equity Research
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
by Zacks Equity Research
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
5 Efficient Stocks to Buy for a Healthy Portfolio
by Tirthankar Chakraborty
Companies with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
Why Heska (HSKA) Could Be Positioned for a Surge
by Zacks Equity Research
Heska (HSKA) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.
5 Top Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide impressive returns as it is positively correlated with the price performance.